|Bid||0.00 x 1800|
|Ask||0.00 x 900|
|Day's Range||11.29 - 12.06|
|52 Week Range||10.49 - 30.13|
|Beta (5Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2022 - Mar 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.50|
--Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA®-- --All three of NGM Bio’s wholly-owned myeloid reprogramming product candidates –NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 – are now in the clinic-- --NGM Bio is implementing a biomarker strategy across NGM707, NGM831 and NGM438 designed to assess t
Shareholders in NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) may be thrilled to learn that the analysts have just...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 6.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?